insurance changes for glp-1 Designing fiscally viable coverage of weight-loss drugs Insurance coverage just changed for

In atherosclerotic disease, GLP-1RAs have been shown to attenuate and stabilize development of atherosclerotic plaques through anti-inflammatory mechanisms (inhibition of IL-6 and TNF-, and NF-B), inhibit activation and recruitment of macrophages and prevent vascular remodeling

Signaling through the GPCR class unites ghrelin, glucagon, glucose-dependent insulinotropic polypeptide (GIP), and glucagon-like peptide (GLP)-1

But in the decades since, it became clear that the bodys resistance to leptin made it ineffective as a standalone treatment for most people with obesity

Contact: Brandyn Bissinger [email protected] Photos accompanying this announcement are available at

(2018) 20 Suppl 1:521

So far, two pills have been approved for use by the U.S